Nektar Therapeutics

NasdaqCM:NKTR Stock Report

Market Cap: US$171.5m

Nektar Therapeutics Management

Management criteria checks 3/4

Nektar Therapeutics' CEO is Howard Robin, appointed in Jan 2007, has a tenure of 17.92 years. total yearly compensation is $3.14M, comprised of 34.6% salary and 65.4% bonuses, including company stock and options. directly owns 0.6% of the company’s shares, worth $1.03M. The average tenure of the management team and the board of directors is 6 years and 16.4 years respectively.

Key information

Howard Robin

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage34.6%
CEO tenure18yrs
CEO ownership0.6%
Management average tenure6yrs
Board average tenure16.4yrs

Recent management updates

Recent updates

Why Investors Shouldn't Be Surprised By Nektar Therapeutics' (NASDAQ:NKTR) 27% Share Price Plunge

Dec 06
Why Investors Shouldn't Be Surprised By Nektar Therapeutics' (NASDAQ:NKTR) 27% Share Price Plunge

Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Oct 18
Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

Jun 19
Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Feb 15
There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Dec 31
Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Nov 06
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Apr 24
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Jan 24
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Aug 19
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Nektar: Time To Abandon Ship

Jul 17

Nektar promotes internal executive to CFO role

Jul 01

We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

May 11
We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

CEO Compensation Analysis

How has Howard Robin's remuneration changed compared to Nektar Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$168m

Jun 30 2024n/an/a

-US$177m

Mar 31 2024n/an/a

-US$176m

Dec 31 2023US$3mUS$1m

-US$276m

Sep 30 2023n/an/a

-US$294m

Jun 30 2023n/an/a

-US$307m

Mar 31 2023n/an/a

-US$415m

Dec 31 2022US$11mUS$1m

-US$368m

Sep 30 2022n/an/a

-US$454m

Jun 30 2022n/an/a

-US$525m

Mar 31 2022n/an/a

-US$491m

Dec 31 2021US$11mUS$1m

-US$524m

Sep 30 2021n/an/a

-US$495m

Jun 30 2021n/an/a

-US$474m

Mar 31 2021n/an/a

-US$429m

Dec 31 2020US$11mUS$1m

-US$444m

Sep 30 2020n/an/a

-US$439m

Jun 30 2020n/an/a

-US$429m

Mar 31 2020n/an/a

-US$460m

Dec 31 2019US$10mUS$1m

-US$441m

Sep 30 2019n/an/a

-US$427m

Jun 30 2019n/an/a

-US$424m

Mar 31 2019n/an/a

US$657m

Dec 31 2018US$13mUS$969k

US$681m

Compensation vs Market: Howard's total compensation ($USD3.14M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Howard's compensation has been consistent with company performance over the past year.

CEO

Howard Robin (71 yo)

18yrs

Tenure

US$3,135,576

Compensation

Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera...

Leadership Team

NamePositionTenureCompensationOwnership
Howard Robin
CEO, President & Director18yrsUS$3.14m0.60%
$ 1.0m
Sandra Gardiner
Chief Financial Officer1.8yrsUS$376.30kno data
Mark Wilson
Senior VP8.5yrsUS$1.10m0.18%
$ 311.9k
Jonathan Zalevsky
Chief Research & Development Officer5.3yrsUS$1.77m0.18%
$ 304.0k
Vivian Wu
Director of Investor Relations & Corporate Affairsno datano datano data
Robert Bacci
Chief People Officer and Head of Quality & Facilities3.1yrsno datano data
Jennifer Ruddock
Chief Business Officer6yrsno datano data
Mary Tagliaferri
Chief Medical Officer7.2yrsno datano data

6.0yrs

Average Tenure

58yo

Average Age

Experienced Management: NKTR's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Howard Robin
CEO, President & Director17.9yrsUS$3.14m0.60%
$ 1.0m
Robert Chess
Independent Chairman of the Board32.7yrsUS$176.22k0.14%
$ 243.3k
R. Greer
Independent Director14.9yrsUS$170.22k0.16%
$ 282.3k
Roy Whitfield
Lead Independent Director24.4yrsUS$170.22k0.16%
$ 267.6k
Jeffrey Ajer
Independent Director7.3yrsUS$134.22k0.019%
$ 31.8k
Diana Brainard
Independent Director3.2yrsUS$112.72k0.012%
$ 20.9k

16.4yrs

Average Tenure

66.5yo

Average Age

Experienced Board: NKTR's board of directors are seasoned and experienced ( 16.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 06:26
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nektar Therapeutics is covered by 33 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Aydin HuseynovBenchmark Company
George FarmerBMO Capital Markets Equity Research